U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C14H27O2.C6H14N2.Pt
Molecular Weight 763.9938
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIRIPLATIN

SMILES

CCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCC(=O)[O-].C1CC[C@]([H])([C@@]([H])(C1)N)N.[Pt+2]

InChI

InChIKey=BGIHRZPJIYJKAZ-BLUNCNMSSA-L
InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1

HIDE SMILES / InChI

Molecular Formula C6H14N2
Molecular Weight 114.189
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C14H27O2
Molecular Weight 227.3635
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Pt
Molecular Weight 195.0778
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Miriplatin hydrate was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Oct 16, 2009. It was developed and marketed as Miripla® by Dainippon Sumitomo Pharma on Jan 20, 2010 in Japan. Miriplatin hydrate is a lipophilic platinum complex that has high affinity to lipiodol. It is indicated for the treatment of transcatheter arterial chemoembolization of hepatocellular carcinoma. Miripla® is available as lyophilized powder for arterial injection, containing 70 mg of free Miriplatin. The recommended dose is 70 mg once daily.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MIRIPLA

Approved Use

Lipiodolization in hepatocellular carcinoma

Launch Date

1.25565115E12
PubMed

PubMed

TitleDatePubMed
Warming effect on miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study.
2013 Oct
Patents

Sample Use Guides

70 mg of miriplatin is suspended in 3.5 mL of suspension vehicle for this drug, and administered once a day through catheter inserted into hepatic artery. Administration of miriplatin-suspension ends when tumor vessel is filled with the drug, provided that the upper limit should be 6 mL per administration (equivalent to 120 mg of miriplatin). An observation period of 4 weeks or longer is required in the case of repeated administration.
Route of Administration: Intra-arterial
Miriplatin (SM-11355) suspended in Lipiodol (SM-11355/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH-109A cells in a dose-dependent manner. IC50 value following 7-day exposure was 22.3 ug/ml.
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:46:15 UTC 2021
Edited
by admin
on Sat Jun 26 15:46:15 UTC 2021
Record UNII
780F0P8N4I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIRIPLATIN
INN   WHO-DD  
INN  
Official Name English
SM-11355
Code English
MIRIPLA
Brand Name English
MIRIPLATIN [MI]
Common Name English
MIRIPLATIN [WHO-DD]
Common Name English
CYCLOHEXANE-(1R,2R)-DIAMINEPLATINUM(II) DIMYRISTATE
Common Name English
MIRIPLATIN [INN]
Common Name English
Code System Code Type Description
EVMPD
SUB34987
Created by admin on Sat Jun 26 15:46:16 UTC 2021 , Edited by admin on Sat Jun 26 15:46:16 UTC 2021
PRIMARY
CAS
141977-79-9
Created by admin on Sat Jun 26 15:46:16 UTC 2021 , Edited by admin on Sat Jun 26 15:46:16 UTC 2021
PRIMARY
PUBCHEM
9832045
Created by admin on Sat Jun 26 15:46:16 UTC 2021 , Edited by admin on Sat Jun 26 15:46:16 UTC 2021
PRIMARY
FDA UNII
780F0P8N4I
Created by admin on Sat Jun 26 15:46:16 UTC 2021 , Edited by admin on Sat Jun 26 15:46:16 UTC 2021
PRIMARY
NCI_THESAURUS
C167007
Created by admin on Sat Jun 26 15:46:16 UTC 2021 , Edited by admin on Sat Jun 26 15:46:16 UTC 2021
PRIMARY
MERCK INDEX
M11894
Created by admin on Sat Jun 26 15:46:16 UTC 2021 , Edited by admin on Sat Jun 26 15:46:16 UTC 2021
PRIMARY
INN
8131
Created by admin on Sat Jun 26 15:46:16 UTC 2021 , Edited by admin on Sat Jun 26 15:46:16 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SALT/SOLVATE -> PARENT